Tags

Type your tag names separated by a space and hit enter

Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature.
J Dtsch Dermatol Ges. 2008 Oct; 6(10):823-7, 823-8.JD

Abstract

SUMMARY

Systemic lupus erythematosus and subacute cutaneous lupus erythematosus (SCLE) occasionally evolve as adverse reactions to a large variety of chemically different drugs. We here report on a 76-year-old woman who developed SCLE within 10 days after initiation of oral terbinafine. Analysis of the 27 cases of terbinafine-induced SCLE in the literature revealed that this disorder has been reported 6 times more often in females than in males. Skin lesions evolved on average around 7 weeks after starting the drug. In 79% of the cases ANA could be detected while antibodies against Ro/SS-A and La/SS-B were found in 86% and 39%, respectively. Remarkably, anti-histone antibodies were present in only 29%. In all cases terbinafine-induced SCLE resolved after discontinuation of the triggering agent. Systemic treatment with anti-malarials and/or corticosteroids does not appear to be mandatory.

Authors+Show Affiliations

Department of Dermatology, University Clinic of Mannheim, Medical School of Mannheim at the University of Heidelberg, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Review

Language

eng ger

PubMed ID

18564209

Citation

Lorentz, Katharina, et al. "Subacute Cutaneous Lupus Erythematosus Induced By Terbinafine: Case Report and Review of Literature." Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, vol. 6, no. 10, 2008, pp. 823-7, 823-8.
Lorentz K, Booken N, Goerdt S, et al. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. J Dtsch Dermatol Ges. 2008;6(10):823-7, 823-8.
Lorentz, K., Booken, N., Goerdt, S., & Goebeler, M. (2008). Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 6(10), 823-7, 823-8. https://doi.org/10.1111/j.1610-0387.2008.06806.x
Lorentz K, et al. Subacute Cutaneous Lupus Erythematosus Induced By Terbinafine: Case Report and Review of Literature. J Dtsch Dermatol Ges. 2008;6(10):823-7, 823-8. PubMed PMID: 18564209.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. AU - Lorentz,Katharina, AU - Booken,Nina, AU - Goerdt,Sergij, AU - Goebeler,Matthias, Y1 - 2008/06/17/ PY - 2008/6/20/pubmed PY - 2009/3/4/medline PY - 2008/6/20/entrez SP - 823-7, 823-8 JF - Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG JO - J Dtsch Dermatol Ges VL - 6 IS - 10 N2 - SUMMARY: Systemic lupus erythematosus and subacute cutaneous lupus erythematosus (SCLE) occasionally evolve as adverse reactions to a large variety of chemically different drugs. We here report on a 76-year-old woman who developed SCLE within 10 days after initiation of oral terbinafine. Analysis of the 27 cases of terbinafine-induced SCLE in the literature revealed that this disorder has been reported 6 times more often in females than in males. Skin lesions evolved on average around 7 weeks after starting the drug. In 79% of the cases ANA could be detected while antibodies against Ro/SS-A and La/SS-B were found in 86% and 39%, respectively. Remarkably, anti-histone antibodies were present in only 29%. In all cases terbinafine-induced SCLE resolved after discontinuation of the triggering agent. Systemic treatment with anti-malarials and/or corticosteroids does not appear to be mandatory. SN - 1610-0387 UR - https://www.unboundmedicine.com/medline/citation/18564209/Subacute_cutaneous_lupus_erythematosus_induced_by_terbinafine:_case_report_and_review_of_literature_ L2 - https://doi.org/10.1111/j.1610-0387.2008.06806.x DB - PRIME DP - Unbound Medicine ER -